CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials
Conclusion: This research showed that CYP17 inhibitors had a significant improvement on prognosis of patients with mCRPC within a relative safety profile both in pre- and post-chemotherapy trials. These expected results provide evidence for the use of CYP17 inhibitors to treat mCRPCs.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Qi Cao Peng Bai Deyao Shi Jiali Liao Hangchuan Shi Yifei Xing Ke Chen Xiaoping Zhang Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Databases & Libraries | Prostate Cancer | Radiography | Science | Study